What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study

References

• American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020.
   Google Scholar
• Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542. doi:10.1001/jama.2017.7248
   PubMed Web of Science ®Google Scholar
• Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Curr Treat Option Oncol. 2016;17(12):64
   PubMed Web of Science ®Google Scholar
• Starosta SB, Savage SJ. Castration-resistant prostate cancer: sequencing oral and infusion agents. Curr Urol Rep. 2018;19(9). doi:10.1007/s11934-018-0826-8
   Web of Science ®Google Scholar
• Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6). doi:10.1101/cshperspect.a030635
   PubMed Web of Science ®Google Scholar
• Gourdin T. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. Curr Opin Oncol. 2019;31(3):188–193. doi:10.1097/CCO.0000000000000521
   Web of Science ®Google Scholar
• Caffo O, Maines F, Kinspergher S, Veccia A, Messina C. Sequencing strategies in the new treatment landscape of prostate cancer. Future Oncol. 2019;15(25):2967–2982. doi:10.2217/fon-2019-0190
   PubMed Web of Science ®Google Scholar
• American Urological Association. AUA white paper on implementation of shared decision making into urological practice 2015 Available from: https://www.auanet.org/guidelines/shared-decision-making. Accessed September 10, 2020.
   Google Scholar
• Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014;64(6):377–388. doi:10.3322/caac.21245
   PubMed Web of Science ®Google Scholar
• Hoffmann TC, Legare F, Simmons MB, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201(1):35–39. doi:10.5694/mja14.00002
   PubMed Web of Science ®Google Scholar
• Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
   PubMed Web of Science ®Google Scholar
• Vromans RD, van Eenbergen MC, Pauws SC, et al. Communicative aspects of decision aids for localized prostate cancer treatment - a systematic review. Urol Oncol. 2019;37(7):409–429.
   PubMed Web of Science ®Google Scholar
• Rooney MK, Morgans AK, Chen RC, et al. Educational material on prostate cancer screening is overly complex and fails to meet recommended layperson readability guidelines. Urology. 2020;135:1–3. doi:10.1016/j.urology.2019.10.006
   Web of Science ®Google Scholar
• Violette PD, Agoritsas T, Alexander P, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65(3):239–251. doi:10.3322/caac.21272
   PubMed Web of Science ®Google Scholar
• Adsul P, Wray R, Spradling K, Darwish O, Weaver N, Siddiqui S. Systematic review of decision aids for newly diagnosed patients with prostate cancer making treatment decisions. J Urol. 2015;194(5):1247–1252.
   Web of Science ®Google Scholar
• Zhong W, Smith B, Haghighi K, Mancuso P. Systematic review of decision aids for the management of men with localized prostate cancer. Urology. 2018;114:1–7. doi:10.1016/j.urology.2017.10.022
   PubMed Web of Science ®Google Scholar
• NIH Office of Behavioral and Social Sciences. Best Practices for Mixed Methods Research in the Health Sciences. 2nd ed. Bethesda: National Institutes of Health; 2018.
   Google Scholar
• Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Method. 2017;29(1):3–22. doi:10.1177/1525822X16639015
   Web of Science ®Google Scholar
• Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer. 2006;106(9):1865–1874. doi:10.1002/cncr.21822
   PubMed Web of Science ®Google Scholar
• Jones RA, Hollen PJ, Wenzel J, et al. Understanding advanced prostate cancer decision making utilizing an interactive decision aid. Cancer Nurs. 2018;41(1):2–10. doi:10.1097/NCC.0000000000000442
   Web of Science ®Google Scholar
• Berry DL, Ellis WJ, Woods NF, Schwien C, Mullen KH, Yang C. Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol. 2003;21(2):93–100. doi:10.1016/S1078-1439(02)00209-0
   PubMed Web of Science ®Google Scholar
• Penedo FJ, Fox RS, Oswald LB, et al. Technology-based psychosocial intervention to improve quality of life and reduce symptom burden in men with advanced prostate cancer: results from a randomized controlled trial. Int J Behav Med. 2020. doi:10.1007/s12529-019-09839-7
   Web of Science ®Google Scholar
• Shaffer VA, Zikmund-Fisher BJ. All stories are not alike: a purpose-, content-, and valence-based taxonomy of patient narratives in decision aids. Med Decis Making. 2013;33(1):4–13. doi:10.1177/0272989X12463266
   PubMed Web of Science ®Google Scholar
• Shaffer VA, Focella ES, Hathaway A, Scherer LD, Zikmund-Fisher BJ. On the usefulness of narratives: an interdisciplinary review and theoretical model. Ann Behav Med. 2018;52(5):429–442. doi:10.1093/abm/kax008
   PubMed Web of Science ®Google Scholar
• Scherr KA, Fagerlin A, Hofer T, et al. Physician recommendations trump patient preferences in prostate cancer treatment decisions. Med Decis Making. 2017;37(1):56–69. doi:10.1177/0272989X16662841
   Web of Science ®Google Scholar
• Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5): djv370
   PubMedGoogle Scholar
• Benidir T, Hersey K, Finelli A, et al. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urol Oncol-Semin Ori. 2018;36(5): 240–e13.
   Web of Science ®Google Scholar
• Pisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer. 2015;121(8):1257–1264. doi:10.1002/cncr.29206
   PubMed Web of Science ®Google Scholar
• de Freitas HM, Ito T, Hadi M, et al. Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries. Adv Ther. 2019;36(2):318–332. doi:10.1007/s12325-018-0861-3
   PubMed Web of Science ®Google Scholar
• Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs. 2002;25(1):42–49. doi:10.1097/00002820-200202000-00009
   PubMed Web of Science ®Google Scholar
• Heyman EN, Rosner TT. Prostate cancer: an intimate view from patients and wives. Urol Nurs. 1996;16(2):37–44.
   PubMedGoogle Scholar
• O’Rourke ME, Germino BB. Prostate cancer treatment decisions: a focus group exploration. Oncol Nurs Forum. 1998;25(1):97–104.
   Google Scholar
• Srirangam SJ, Pearson E, Grose C, Brown SC, Collins GN, O’Reilly PH. Partner’s influence on patient preference for treatment in early prostate cancer. BJU Int. 2003;92(4):365–369. doi:10.1046/j.1464-410X.2003.04355.x
   Web of Science ®Google Scholar
• Adamson M, Choi K, Notaro S, Cotoc C. The doctor-patient relationship and information-seeking behavior: four orientations to cancer communication. J Palliat Care. 2018;33(2):79–87. doi:10.1177/0825859718759881
   PubMed Web of Science ®Google Scholar
• Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 2001;19(1):72–80. doi:10.1200/JCO.2001.19.1.72
   PubMed Web of Science ®Google Scholar